Final Prospectus · 424B4
Erasca, Inc.
ERASNASDAQEQUITYCurrent
Final Prospectus
Company context
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Current securities
Recent company filings
- Other EventsNov 20, 2026
- SCHEDULE 13G/A - filed by RTW INVESTMENTS, LP regarding Erasca, Inc.Nov 16, 2026
- Results of Operations and Financial ConditionNov 12, 2026
- 10-Q filingNov 12, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 16, 2026